Ocugen upgraded by Chardan Capital Markets with a new price target
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Chardan Capital Markets upgraded Ocugen from Neutral to Buy and set a new price target of $3.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2024 | $4.00 | Buy | Maxim Group |
| 3/1/2023 | $3.50 | Neutral → Buy | Chardan Capital Markets |
| 8/23/2022 | $5.00 | Buy | Mizuho |
| 6/15/2022 | $8.00 | Buy | ROTH Capital |
| 6/2/2022 | $4.50 | Overweight | Cantor Fitzgerald |
| 2/28/2022 | $10.00 → $8.00 | Buy | HC Wainwright & Co. |
| 7/26/2021 | Outperform | Noble Capital Markets |
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)